Abstract
BackgroundPrognosis and OS are poor in patients with advanced or recurrent endometrial cancer (EC). First-line standard of care for these patients is paclitaxel-carboplatin chemotherapy; however, more effective and tolerable therapies...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have